HENDERSON, Nev., Aug. 24, 2022 (GLOBE NEWSWIRE) -- BioLife Sciences Inc. (“BioLife” or the “Company”) (OTC: BLFE) announced today that it will be expanding the scope of its orthomolecular medicine and natural health products division, with a specific focus on disruptive hemp products.
The Company will focus on new and innovative product infusions centered around North American Grown, third-party tested industrial hemp geared towards providing consumers with an array of new and more effective options.
BioLife will be focused on throat and cough syrups infused with cannabinoids, cannabinoid-infused teas and CBD Energy Shots.
Additionally, the Company will focus on pet products infused with cannabinoids which offer wellness support for cats and dogs.
BioLife is confident in the abilities of CBD and cannabinoid-infused products to not only disrupt the relatively newly formed hemp industry, but additionally in these products ability to assist both humans and pets by supporting everyday health, well-being and anxiety-relief.
Nika Jaksic, COO of BioLife Sciences, stated: “We are so thrilled that BioLife will be focusing on this stream of business focusing on products in the marketplace which are not only disruptors, but that are beneficial and useful products for consumers to seek out.”
“Some view this market as already being over-saturated,” Jaksic said, “however, at BioLife, we are confident that this sector will continue to grow in the coming years and consumers as a whole are moving towards more holistic approaches such as CBD, CBG and CBN. Consumers are continuing to become more aware of the benefits of CBD, and other cannabinoids, for not just humans, but for pets too.
https://www.globenewswire.com/news-release/2022/08/24/2503722/0/en/BioLife-Sciences-Inc-Expands-Product-Offerings-in-the-Orthomolecular-Medicine-and-Natural-Health-Markets-with-a-Focus-on-Hemp-Products.html